论文信息 - A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/- nab-paclitaxel in patients with pancreatic cancer. - 字舞流文

A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/- nab-paclitaxel in patients with pancreatic cancer.

A. Carrato | M. Hidalgo | J. Dupont | M. Jeffery | P. Grimison | N. Tebbutt | E. Holmgren | A. Kapoun | F. Parnis | P. Cooray | M. Jameson | R. Stagg